US · Healthcare · Biotechnology
EPS came in at -0.52 against a street estimate of -0.48 — a miss of 8.3%.
Analysts rate NewAmsterdam Pharma Company N.V. Ordinary Shares a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $50.89.
CONFIDENT NAMS highlighted obicetrapib's multi-faceted benefits beyond LDL-lowering, including HDL increases and Alzheimer's biomarker improvements. PREVAIL interim readout expected Q1 2027; management encouraged by BROADWAY 21% MACE reduction and similar event tracking. FY2026 Investor Day (Aug 5, 2026) EMA CHMP recommends approval; US regulatory decision contingent on PREVAIL interim (Q1 2027). No revenue guidance provided. No analyst Q&A segment occurred; call was executive presentation format only. Management did not address competitive threats (HORIZON, OCEANA) or revenue timing beyond noting event-rate comparisons and regulatory pathway. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 14.17% |
| Capital World Investors | 10.23% |
| RA Capital Management, LLC | 7.99% |
| FCPM III SERVICES BV | 7.70% |
| FMR Inc | 7.33% |
| Bain Capital Life Sciences Investors, LLC | 6.11% |
| Deerfield Management Co | 3.57% |
| Viking Global Investors LP | 3.52% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. – 8-K SUMMARY HEADLINE NUMBERS • New Principal Accounting Officer appointed: Robert W. Gunning, age 55, effective A | 2026-08-14 |
| Quarterly report · Q2 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — FORM 10-Q SUMMARY For the quarterly period ended June 30, 2026 --- HEADLINE NUMBERS • Cash position: $424.2 mill | 2026-08-05 |
| Results announced · Q3 2026 NEWAMSTERDAM PHARMA - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $678.3 million (cash, cash equivalents, and marketable securities) | 2026-08-05 |
| Company announcement · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — 8-K SUMMARY HEADLINE NUMBERS • Company: NewAmsterdam Pharma Company N.V., Netherlands-based pharmaceutical compan | 2026-07-24 |
| Board / officer change · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. – 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this 8-K filing • Document filed July 22, 2026, repo | 2026-07-22 |
| Quarterly report · Q1 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $457.6 million in cash and cash equivalents as of March 31 | 2026-05-07 |
| Proxy statement · Q2 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Adoption of Dutch statutory annual accounts | 2026-05-06 |
| Annual report FY2025 NEWAMSTERDAM PHARMA COMPANY N.V. — 10-K SUMMARY HEADLINE NUMBERS • Market capitalization (non-affiliate shares): $1,345,893,076 as of June 30, 2025 | 2026-02-18 |
Readable in the app.
| Announcement | Date |
|---|---|
| PREVAIL interim analysis planned for 4Q26 with results expected in 1Q27 NewAmsterdam Pharma, a clinical-stage biotech company, reported Q1 2026 results with strong progress on its lead drug obicetrapib, which treats high cholesterol in cardiovascular disease pat | 2026-05-07 |
| Regulatory approval decisions expected 2H26; Phase 3 trial data timelines provided NewAmsterdam Pharma reported full-year 2025 results for its lead drug obicetrapib, a cholesterol-lowering treatment for cardiovascular disease patients. Key highlights: The company's Marketi | 2026-02-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NewAmsterdam Pharma Company N.V. Ordinary Shares — free to start.
Google PlayApp StoreData updated 2026-09-18.